Iododoxorubicin (BioDeep_00000180060)
human metabolite blood metabolite
代谢物信息卡片
化学式: C27H28INO10 (653.0757898)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 83.33%
分子结构信息
SMILES: CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)I
InChI: InChI=1S/C27H28INO10/c1-10-22(28)13(29)6-17(38-10)39-15-8-27(36,16(31)9-30)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,30,33,35-36H,6-9,29H2,1-2H3
描述信息
同义名列表
4 个代谢物同义名
10-[(4-amino-5-iodo-6-methyloxan-2-yl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; 10-[(4-amino-5-iodo-6-methyloxan-2-yl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione; 7-(4-amino-5-iodo-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; Iododoxorubicin
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Bruce D Cheson, Bart Barlogie, Robert A Kyle, Giovanni Palladini, Susan M Geyer, Giampaolo Merlini. A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
2002 Mar; 9(1):24-30. doi:
10.3109/13506120209072441. [PMID: 12000194] - O Sezer, K Niemöller, C Jakob, C Langelotz, J Eucker, K Possinger. Novel approaches to the treatment of primary amyloidosis.
Expert opinion on investigational drugs.
2000 Oct; 9(10):2343-50. doi:
10.1517/13543784.9.10.2343. [PMID: 11060811] - O Sezer, J Eucker, C Jakob, K Possinger. Diagnosis and treatment of AL amyloidosis.
Clinical nephrology.
2000 Jun; 53(6):417-23. doi:
NULL. [PMID: 10879660] - J A Palha, D Ballinari, N Amboldi, I Cardoso, R Fernandes, V Bellotti, G Merlini, M J Saraiva. 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.
The American journal of pathology.
2000 Jun; 156(6):1919-25. doi:
10.1016/s0002-9440(10)65065-1. [PMID: 10854215] - E Pérez Equiza, J M Arguiñano, J Gastearena. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin.
Haematologica.
1999 Jan; 84(1):93-4. doi:
NULL. [PMID: 10091401] - P N Hawkins, C Aprile, G Capri, L Viganò, E Munzone, L Gianni, M B Pepys, G Merlini. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.
European journal of nuclear medicine.
1998 Jul; 25(7):701-8. doi:
10.1007/s002590050272. [PMID: 9662591] - L P Rivory, K M Avent, S M Pond. Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin.
Cancer chemotherapy and pharmacology.
1996; 38(5):439-45. doi:
10.1007/s002800050508. [PMID: 8765437] - G Merlini, E Ascari, N Amboldi, V Bellotti, E Arbustini, V Perfetti, M Ferrari, I Zorzoli, M G Marinone, P Garini. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
Proceedings of the National Academy of Sciences of the United States of America.
1995 Mar; 92(7):2959-63. doi:
10.1073/pnas.92.7.2959. [PMID: 7708755] - C J Twelves, N A Dobbs, M A Lawrence, A J Ramirez, M Summerhayes, M A Richards, K E Towlson, R D Rubens. Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.
British journal of cancer.
1994 Apr; 69(4):726-31. doi:
10.1038/bjc.1994.137. [PMID: 8142261] - M Strolin Benedetti, D Fraier, E Pianezzola, M G Castelli, P Dostert, L Gianni. Stereoselectivity of iododoxorubicin reduction in various animal species and humans.
Xenobiotica; the fate of foreign compounds in biological systems.
1993 Feb; 23(2):115-21. doi:
10.3109/00498259309059367. [PMID: 8498075] - L P Rivory, S M Pond, D J Winzor. The influence of pH on the interaction of lipophilic anthracyclines with bovine serum albumin. Quantitative characterization by measurement of fluorescence quenching.
Biochemical pharmacology.
1992 Dec; 44(12):2347-55. doi:
10.1016/0006-2952(92)90679-d. [PMID: 1472099] - E Friche, M K Danks, W T Beck. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Cancer research.
1992 Oct; 52(20):5701-6. doi:
. [PMID: 1356619] - J Robert, J P Armand, S Huet, M Klink-Alakl, G Recondo, P Hurteloup. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1992 Jul; 10(7):1183-90. doi:
10.1200/jco.1992.10.7.1183. [PMID: 1607922] - D M Edwards, P Marrari, C Efthymiopoulos, G Basileo, D Fraier, E Pianezzola, M Strolin-Benedetti. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Drug metabolism and disposition: the biological fate of chemicals.
1991 Sep; 19(5):938-45. doi:
NULL. [PMID: 1686240] - K B Mross, T Langenbuch, K Burk, D K Hossfeld. [Iodo-doxorubicin, a new anthracycline derivative. Current state of progress].
Onkologie.
1990 Oct; 13(5):346-51. doi:
10.1159/000216794. [PMID: 2082229] - K Mross, U Mayer, K Hamm, D K Hossfeld. High-performance liquid chromatography of iodo-doxorubicin and fluorescent metabolites in plasma samples.
Journal of chromatography.
1990 Aug; 530(1):192-9. doi:
10.1016/s0378-4347(00)82321-x. [PMID: 2277112] - L Gianni, L Viganò, A Surbone, D Ballinari, P Casali, C Tarella, J M Collins, G Bonadonna. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Journal of the National Cancer Institute.
1990 Mar; 82(6):469-77. doi:
10.1093/jnci/82.6.469. [PMID: 2313718] - K Mross, U Mayer, K Hamm, K Burk, D K Hossfeld. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
European journal of clinical pharmacology.
1990; 39(5):507-13. doi:
10.1007/bf00280945. [PMID: 2076745] - K Mross, U Mayer, T Langenbuch, K Hamm, K Burk, D Hossfeld. Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients.
European journal of cancer (Oxford, England : 1990).
1990; 26(11-12):1156-62. doi:
10.1016/0277-5379(90)90276-y. [PMID: 2149998] - B Schott, J Robert. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
Biochemical pharmacology.
1989 Nov; 38(22):4069-74. doi:
10.1016/0006-2952(89)90688-6. [PMID: 2597184] - F Formelli, R Carsana, C Pollini. Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin.
Cancer research.
1987 Oct; 47(20):5401-6. doi:
NULL. [PMID: 3652044] - G Capranico, A Riva, S Tinelli, T Dasdia, F Zunino. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Cancer research.
1987 Jul; 47(14):3752-6. doi:
NULL. [PMID: 3474061]